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A recent editorial1 by Mintzes and colleagues warns about using
flawed clinical trials to approve new cancer drugs in Europe2
and the US.3 The implications go further, however: during the
past decade, several Latin American countries have adopted
regulations that abbreviate the approval process of new drugs
in the case of earlier approval by the European Medicines
Agency (EMA) or the US Food and Drug Administration (FDA).
Between 2012 and 2017 the Mexican regulator approved,
through an accelerated procedure, 310 new drugs already
authorised by the FDA, EMA, and Australian, Canadian, and
Swiss regulators.4 In 2011 Ecuador launched a standardisation
process of marketing authorisation. Current regulation
establishes standardisation with the FDA, EMA, and several
other national regulators. In 2016 Argentina authorised 15 new
drugs through a similar process; only four showed some added
therapeutic value.5
Furthermore, the EMA and FDA implemented regulations to
shorten the marketing authorisation process of certain drugs.
Under these programmes, drugs are authorised on the basis of
phase II trials, single arm trials, and surrogate end points.6
Consequently, whenever a drug is authorised by the EMA or
FDA through an accelerated process, it can be quickly registered
in several Latin American countries. Studies have shown that
most cancer drugs that initially show positive results on
surrogate outcomes later have disappointing results on overall
survival.7 3 Latin American regulators are seldom able to react,
for example by revoking the authorisation when new evidence
emerges. This leads to other problems that can result in financial
risks to their healthcare systems, such as lawsuits and increased
pressure to reimburse the drug or include it on public
procurement lists.
We join the call to raise the bar for the approval of new cancer
drugs.1 8 The EMA, FDA, and other international regulatory
authorities must think globally to protect patients worldwide.
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